SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Keith Feral2/25/2008 10:37:14 AM
Read Replies (1) of 418
 
Adventrx added a new board member from Imclone today, who was the chief medical officer at Imclone.

Vinorelbine - awaiting NDA.
Docetaxel - awaiting phase 3 bioequivalence trial this month.
Cofactor - DOA from the phase 2 b. They may get more success in breast cancer and avastin trials.

The main drug now is docetaxel. This is the only one that can get Adventrx back in the game. Since it eliminates all hypersensitivity, their drug could gain almost exclusive control of the generic market when it goes off patent for the first couple of years.

I'm thinking of buying back the shares I sold last year to get my losses out of the way.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News